J Breast Cancer.  2017 Mar;20(1):112-113. 10.4048/jbc.2017.20.1.112.

Comment on “Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer”

• Altundag K

• KMID: 2379407
• DOI: http://doi.org/10.4048/jbc.2017.20.1.112

Abstract

No abstract available.

MeSH Terms

Breast*
Humans
Ventricular Dysfunction, Left*

Reference

1. Yoon HJ, Kim KH, Kim JY, Park HJ, Cho JY, Hong YJ, et al. Chemotherapy-induced left ventricular dysfunction in patients with breast cancer. J Breast Cancer. 2016; 19:402–409.

2. de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol. 2014; 32:2159–2165.

3. Zardavas D, Suter TM, Van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, et al. Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy. J Clin Oncol. 2017; 35:878–884.

4. Beer LA, Kossenkov AV, Liu Q, Luning Prak E, Domchek S, Speicher DW, et al. Baseline immunoglobulin E levels as a marker of doxorubicin-and trastuzumab-associated cardiac dysfunction. Circ Res. 2016; 119:1135–1144.